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According to the latest update by the International WHO Agency
for Research on Cancer http://www.iarc.fr/en/media-centre/pr/
2013/pdfs/pr223_E.pdf, there were about 14 million new cases of
cancer and 8 million deaths owing to this disease in 2012. Projec-
tions suggest that there will be approximately 20 million new
cases per year in the not-so-distant year 2025. The most commonly
diagnosed cancers worldwide are lung (13.0% of the total), breast
(11.9% of the total), and colorectal (9.7% of the total) cancers with
deaths from lung, liver and stomach cancer being in the top 3.
These statistics are alarming but highlight the need for innovative,
multi-disciplinary and joint ventures to battle cancer.
Our understanding of cancer initiation and progression has
increased exponentially since the ﬁrst proto-oncogene, Ras, was
identiﬁed in 1993. Genetics and epigenetics play a major role in
our molecular understanding of the pathogenesis of cancer, as
cancer is predominantly a genetic disease. Numerous research
groups all over the world, including those of Bert Vogelstein,
Robert Weinberg, Douglas Hannahan, Scott Lowe, Tyler Jacks, Tak
Mak, Julian Downward, Michael Karin and the late Stanley
Korsmeyer to mention a few, have contributed signiﬁcantly to
the advances made in the ﬁeld. Numerous publications using
animal models, in vitro cell culture, genome wide association
studies and samples from cancer patients have demonstrated that
cancer-causing signaling pathways are complex and inﬂuenced by
multiple insults. Distinct genes initiate and maintain the cancer
phenotype and are the target of therapeutic intervention. Targeted
therapy has worked well for some cancers, such as Her2 inhibitors
for breast cancer and c-ABL inhibitors for leukemia. However, there
is a great need to rethink drug discovery strategies as we move
forward, and we are in dire need for a better understanding of
pathways regulating the appearance, growth and propagation of
cancer cells and how multiple pathways are connected.
This Special Issue attempts to inform and encourage cancer
researchers to think about several emerging avenues in cancer
signaling involving tumor suppression. The review by Dr. Giancotti
on how a cancer cell undergoes dysregulation provides a compre-
hensive introduction to the topic. Several contributions describe
emerging aspects of p53 biology, including novel roles for cytoplas-
mic p53 (Comel et al.) and p53-mediated regulation of several
microRNAs (Li et al.). Tumor-associated microRNAs and theirpotential in personalized cancer therapy are also discussed in this
Special Issue. Updates on numerous tumor suppressor pathways,
including PML, RASSF, angiomotins, VHL, ING and NF2/Merlin,
are comprehensively described in several reviews. A contribution
on pyruvate kinase M2 (PKM2) (Iqbal et al.) emphasizes that can-
cer can be considered a metabolic disease due to the switch from
aerobic metabolism to anaerobic metabolism during growth and
metastasis. This review highlights the imperative need to under-
stand the energetic state of tumor cells, so as to design novel ther-
apeutics capable of starving the cell of this energy source and
inducing its demise. Lastly, a timely review on autotaxin (Benesch
et al.) underscores the importance of the microenvironment of a
tumor cell in the complex interplay between stromal and tumor
factors. Autotaxin is a secreted enzyme that regulates the produc-
tion of lysophosphatidate, which is involved in regulating growth
and migration of cells, and is a ﬁeld that warrants attention.
As we learn more about the complex molecular circuitries that
suppress tumor growth and progression, extensively reviewed in
this Special Issue, we might stand a better chance at ﬁnding ways
to eradicate cancer through rational drug design. Bert Vogelstein
estimated several years ago that over 90% of cancer-causing genes
are mutated tumor suppressor genes rather than oncogenes. Thus,
understanding the molecular mechanisms involved in tumor
suppression will greatly aid in the battle against cancer.
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